Form 4: Crinetics Pharmaceuticals' Chief Scientific Officer Sells Shares to Cover Tax Obligations

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold shares of common stock on March 19, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold shares of the company's common stock on March 19, 2025.
• The sales were executed to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) granted on February 28, 2022, March 1, 2023, and March 4, 2024.
• A total of 5,479 shares were sold at a volume weighted average price of $34.17 per share, with prices ranging from $33.78 to $34.77.
• An additional 291 shares were sold at a volume weighted average price of $34.83 per share, with prices ranging from $34.78 to $35.00.
• The sales were conducted through open market transactions under a pre-arranged Rule 10b5-1 trading plan.
• Following the reported transactions, Betz beneficially owns 108,588 shares of Crinetics Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. The stock sale is related to tax obligations and executed under a pre-arranged trading plan, so it doesn't necessarily reflect a change in the insider's view of the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading by corporate insiders. They do not necessarily indicate a change in the company's prospects.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small number of shares involved.

Key Dates

Keywords

Crinetics Pharmaceuticals, Stephen F. Betz, insider trading, Form 4, share sale, tax obligations, Restricted Stock Units, Rule 10b5-1 trading plan, CRNX